DaVita Inc. and Humana have launched a value-based care partnership to serve more than 10,000 Medicare Advantage beneficiaries with stages 3B to 5 chronic kidney disease. The agreement, which began on July 1, expands an existing collaboration that previously focused on end-stage renal disease.
The program, delivered through DaVita Integrated Kidney Care (DaVita IKC), will provide coordinated care aimed at stabilizing kidney function and slowing disease progression. Services include cardiovascular, renal, and metabolic health management, along with guidance on treatment options such as home dialysis and kidney transplants. The partnership also addresses barriers to care, including nutritional support, transportation assistance, and mental health needs.
DaVita’s network supporting the initiative includes approximately 3,000 partner nephrologists. As of June 30, 2026, the company served about 298,500 patients globally across 3,266 outpatient dialysis centers, including 2,671 in the United States and 595 in 14 other countries. The partnership targets patients in early-to-mid stages of chronic kidney disease, where disease decline often accelerates but is frequently underdiagnosed or undertreated.
Dr. Sonia Samagh, National Medical Director of DaVita IKC, highlighted the clinical significance, stating that early interventions are transforming patient outcomes in kidney care.
